Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | KLK7 | P49862 | 5/20 | 0.47 |
| ▸ | MME | P08473 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13345404 | 1.00 | MEN1 (0.49) | MEN1KMT2APOLBL3MBTL1HDAC2 | |
| SCHEMBL13345396 | 1.00 | MEN1 (0.49) | MEN1KMT2APOLBL3MBTL1HDAC2 | |
| SCHEMBL11569906 | 0.83 | MME (0.56) | MEN1KMT2APOLBL3MBTL1MAPT | |
| SCHEMBL10791680 | 0.82 | LTA4H (0.53) | MEN1KMT2APOLBL3MBTL1MAPT | |
| SCHEMBL13345388 | 0.82 | HDAC2 (0.57) | MEN1KMT2APOLBL3MBTL1HDAC2 | |
| SCHEMBL29006058 | 0.82 | HDAC2 (0.57) | MEN1KMT2APOLBL3MBTL1HDAC2 | |
| SCHEMBL17548799 | 0.81 | MAPT (0.53) | MEN1KMT2APOLBHDAC2MAPT | |
| SCHEMBL31146150 | 0.81 | ALDH1A1 (0.53) | MEN1KMT2APOLBL3MBTL1MAPT | |
| SCHEMBL8151057 | 0.80 | HDAC2 (0.67) | HDAC2ALDH1A1LMNA | |
| SCHEMBL4747179 | 0.79 | POLB (0.50) | MEN1KMT2APOLBL3MBTL1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113504-A1 | AMIDE COMPOUNDS AND THEIR USE AS ANTITUMOR AGENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113504-A1 | AMIDE COMPOUNDS AND THEIR USE AS ANTITUMOR AGENTS | HDAC3, HCCS, CCNH | MEN1 4354/4885KMT2A 1274/4885POLB 2060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.